Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Phase 1 trial records — page 9

226 records at phase 1.

Showing 0 records on this page

Records

226 documents · page 9 of 10

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
HEX-PH1-GHHexarelinPhase 1ReportedPhase 1 ascending dose1995Low
GHRP6-PH1-GHGHRP-6Phase 1ReportedPhase 1 ascending dose1995Low
HEX-PH1-GH-DDIprogramme recordHexarelinPhase 1ReportedRandomised crossover1995Very low
GHRP6-PH1-GH-OLEprogramme recordGHRP-6Phase 1ReportedSingle-arm open-label1995Very low
HEX-PH1-GH-HEPATIC-IMPprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
GHRP6-PH1-GH-ELDERLYprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
HEX-PH1-GH-RENAL-IMPprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
GHRP6-PH1-GH-BIOMARKERprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
HEX-PH1-GH-PKprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
GHRP6-PH1-GH-ADHERENCEprogramme recordGHRP-6Phase 1ReportedObservational1995Very low
HEX-PH1-GH-OLEprogramme recordHexarelinPhase 1ReportedSingle-arm open-label1995Very low
GHRP6-PH1-GH-QOLprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
AMY-PH1-ORALprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
AMY-PH1B-SCprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
TRIUMPH-1-RENAL-IMPprogramme recordRetatrutidePhase 1OngoingPhase 1 ascending doseVery low
REDEFINE-4-RENAL-IMPprogramme recordCagriSema (cagrilintide with semaglutide)Phase 1OngoingPhase 1 ascending doseVery low
SYNCHRONIZE-CVOT-RENAL-IMPprogramme recordSurvodutidePhase 1OngoingPhase 1 ascending doseVery low
MARITIDE-PH3-RENAL-IMPprogramme recordMaridebart cafraglutidePhase 1OngoingPhase 1 ascending doseVery low
EPI-RU-ELDERLY-PKprogramme recordEpithalonPhase 1ReportedPhase 1 ascending doseVery low
SELANK-RU-ANXIETY-DDIprogramme recordSelankPhase 1ReportedRandomised crossoverVery low
GNRH-PULSATILE-HH-PKprogramme recordGonadorelinPhase 1ReportedPhase 1 ascending doseVery low
SERM-DIAGNOSTIC-DDIprogramme recordSermorelinPhase 1ReportedRandomised crossoverVery low
TRIUMPH-1-PKprogramme recordRetatrutidePhase 1OngoingPhase 1 ascending doseVery low
REDEFINE-4-PKprogramme recordCagriSema (cagrilintide with semaglutide)Phase 1OngoingPhase 1 ascending doseVery low

page 9 of 10

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.